Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

• Conditions: Kidney Allograft Fibrosis; Kidney Transplant Failure and Rejection

• Registration Number: NCT03487861
• Lead Sponsor: Asan Medical Center

Brief Summary

The aim of this study is to verify the ability of transglutaminase type 2 to predict rejection or chronic allograft nephropathy of renal allograft. On the basis of biomolecular mechanisms aggravating chronic allograft nephropathy, we eventually expect to develop the remedy to prevent chronic allograft nephropathy after kidney transplantation.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-29
• Study First Submitted: 2018-03-18
• Status Verified: 2018-04
• Study First Submitted QC: 2018-04-03
• Last Update Submitted: 2018-04-03
• Study First Posted: 2018-04-04
• Last Update Posted: 2018-04-04
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• kidney transplant recipients from cadaveric or living donors
• kidney transplant recipients who take immunosuppressants regularly
• kidney transplant recipients who voluntarily agree to participate in this trial

Read More

Exclusion Criteria

• multiorgan transplant recipients
• kidney transplant recipients with active infection
• kidney transplant recipients with alcohol or drug addiction

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change of level of urinary transglutaminase 2	3 days, 7 days, 1 month, 3 months, 6 months post-transplant

Trial Locations

Locations (1)

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of